Compounds / GHRP-6
Growth Hormone His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

GHRP-6

The first-generation synthetic GHRP with strong GH-releasing and appetite-stimulating activity, foundational to understanding the ghrelin receptor system.

Overview

GHRP-6 is a synthetic hexapeptide and the first-generation GHRP, developed by Cyril Bowers in the 1980s. It was instrumental in characterizing the ghrelin receptor (GHS-R1a) and established the GHRP class as a viable approach to GH stimulation. Compared to later GHRPs (GHRP-2, ipamorelin), GHRP-6 produces stronger appetite stimulation due to its more pronounced effect on hypothalamic ghrelin receptors and NPY/AgRP neurons. GHRP-6 remains widely used in research as a reference compound and for studies specifically examining appetite regulation, gastric motility, and GH secretion simultaneously.

Mechanism

GHRP-6 activates GHS-R1a on both pituitary somatotrophs (producing GH release) and hypothalamic neurons (producing appetite stimulation and modulating GH pulse amplitude). It also mildly stimulates prolactin and ACTH/cortisol release. The appetite-stimulating effect is mediated through hypothalamic NPY and AgRP pathways, which ghrelin receptor activation upregulates. This effect distinguishes GHRP-6 from GHRP-2 (less appetite stimulation) and ipamorelin (minimal appetite effect).

Research Areas

Growth hormone secretionAppetite regulation and ghrelin pathway researchGastric motility (gastroparesis models)Cardiac protection (preclinical)Cachexia and appetite restoration research

Side Effects (Preclinical)

  • Strong appetite stimulation (primary differentiator from newer GHRPs)
  • Cortisol and prolactin elevation
  • Flushing
  • Water retention
  • Transient fatigue post-injection

Cautions

  • For research use only
  • Appetite stimulation relevant consideration in research designs measuring food intake
  • Cortisol elevation may confound studies requiring stable HPA axis function

What the research shows

GHRP-6’s strong appetite-stimulating effect — sometimes framed as a limitation — has also made it the preferred research tool for ghrelin pathway studies and cachexia/appetite restoration models. Its role in characterizing the ghrelin receptor earned it a place in foundational peptide pharmacology.

For researchers primarily interested in GH release with minimal confounders, ipamorelin has largely replaced GHRP-6. For appetite and GI motility research, GHRP-6’s pronounced ghrelin-mimetic effects remain useful.